Johnson & Johnson (JNJ) Net Cash Flow (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Net Cash Flow came in at $2.0 billion in Q1 2026, down 85.99% year-on-year from $14.3 billion in Q1 2025, and up 37.73% quarter-over-quarter from $1.5 billion in Q4 2025.
Johnson & Johnson (JNJ) Net Cash Flow (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Net Cash Flow across 18 years of filings, most recently posting $2.0 billion for Q1 2026.
- Net Cash Flow for Q1 2026 came in at $2.0 billion, down 85.99% year-over-year; the trailing twelve-month figure through Mar 2026 was -$16.9 billion (down 229.0% YoY), and the FY2025 annual result was -$4.6 billion, down 281.34% from the prior year.
- Net Cash Flow came in at $2.0 billion for Q1 2026 at Johnson & Johnson, up from $1.5 billion in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $14.3 billion in Q1 2025 to a low of -$20.1 billion in Q2 2025.
- The 5-year median for Net Cash Flow is -$300.0 million (2025), against an average of -$3.1 million.
- Across the five-year window, Net Cash Flow soared 414.6% in 2023 and sank 3831.57% in 2025, its largest moves.
- Johnson & Johnson's Net Cash Flow stood at -$4.0 billion in 2022, then soared by 149.65% to $2.0 billion in 2023, then jumped by 115.5% to $4.3 billion in 2024, then slumped by 66.34% to $1.5 billion in 2025, then soared by 37.73% to $2.0 billion in 2026.
- The last three Net Cash Flow figures came in at $2.0 billion (Q1 2026), $1.5 billion (Q4 2025), and -$300.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 210.32 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | -2.05 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 2.00 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 4.17 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -9.27 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 75.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 544.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -587.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 2.00 Bn |
| Mar 29, 2026 | 2.00 Bn |
| Dec 28, 2025 | 1.46 Bn |
| Dec 28, 2025 | 1.46 Bn |
| Sep 28, 2025 | -300.00 Mn |
| Sep 28, 2025 | -300.00 Mn |
| Jun 29, 2025 | -20.05 Bn |
| Jun 29, 2025 | -20.05 Bn |
| Mar 30, 2025 | 14.30 Bn |
| Mar 30, 2025 | 14.30 Bn |
| Dec 29, 2024 | 4.32 Bn |
| Dec 29, 2024 | 4.32 Bn |
| Sep 29, 2024 | -5.02 Bn |
| Sep 29, 2024 | -5.02 Bn |
| Jun 30, 2024 | -510.00 Mn |
| Jun 30, 2024 | -510.00 Mn |
| Mar 31, 2024 | 3.74 Bn |
| Mar 31, 2024 | 3.74 Bn |
| Dec 31, 2023 | 2.01 Bn |
| Dec 31, 2023 | 2.01 Bn |